These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [Abstract] [Full Text] [Related]
11. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation. Kinoshita S, Yoshioka K, Kasahara M, Takamiya O. Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773 [Abstract] [Full Text] [Related]
15. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications. Hilbert L, Federici AB, Baronciani L, Dallagiovanna S, Mazurier C. Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475 [Abstract] [Full Text] [Related]
17. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease. Johnstone IB, Crane S. Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674 [Abstract] [Full Text] [Related]
18. Von Willebrand's disease: case report and review of literature. Echahdi H, El Hasbaoui B, El Khorassani M, Agadr A, Khattab M. Pan Afr Med J; 2017 Apr; 27():147. PubMed ID: 28904675 [Abstract] [Full Text] [Related]